2022

Jul 14

• 

• OraSure Technologies Launches New Product for Microbiome Researchers to Study DNA and RNA

  BETHLEHEM, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its OMNIgene ® •GUT DNA and RNA product ( OMR-205 ) is now available to gut microbiome...

Apr 07

• 

• Orasure technologies’ subsidiary DNA Genotek launches the first device with de novo authorization from the FDA for the preservation and stabilization of microbiome samples

  BETHLEHEM, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today its OMNIgene®·GUT Dx (OMD-200) microbiome collection device, has been granted de novo authorization from the U.S. Food and Drug Administration (FDA) and the Company is commercially launching the device...

Mar 31

• 

• OraSure Technologies’ Subsidiary Diversigen Launches Metatranscriptomic Sequencing and Analysis Services for Gut Microbiome Samples

  BETHLEHEM, Pa., March 31, 2022 (GLOBE NEWSWIRE) - OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its’ Diversigen subsidiary has launched a new service to provide metatranscriptomic sequencing and analysis of gut microbiome samples...